- In June 2024, Johnson & Johnson MedTech announced that DePuy Synthes received FDA clearance for VELYS Robotic-Assisted Solution in Unicompartmental Knee Arthroplasty (UKA) clinical application. The application is for medical & lateral procedures and is expected to help surgeons in guiding precise implant placement with no CT scan
- In April 2024, Xstim announced that it received premarket approval for Xstim spine fusion stimulator from the U.S. FDA. It is a non-invasive, wearable bone growth stimulation device which emits low-energy signal promoting bone healing after spinal fusion surgery of patients
- In December 2023, Orthofix Medical Inc. announced the new data that supported the safety and efficacy of PEMF Stimulation in Lumbar Spine Fusion Procedures indicated for patients with the risk of pseudarthrosis
- In May 2022, Orthofix Medical Inc. (U.S.) obtained FDA premarket approval for the AccelStim Bone Growth Stimulation Device. This approval signifies that the device has met the necessary regulatory requirements and can now be marketed and sold in the United States. The AccelStim Bone Growth Stimulation Device is expected to offer advanced therapeutic options for promoting bone healing and treating fractures effectively
- In March 2022, the corporation announced the competition of ZimVie, its offshoot. The separation represents a significant step forward in Zimmer Biomet's active portfolio management
- In October 2021, Bioventus completed the acquisition of Misonix, a regenerative medicine and minimally invasive ultrasonic technology therapeutics provider. This acquisition would help the company to enhance its offerings for bone growth stimulators and products
